About Pathway Therapeutics
Pathway Therapeutics is a company based in San Francisco (United States) founded in 2008 was acquired by VetDC in August 2013. Pathway Therapeutics has raised $28.85 million across 6 funding rounds from investors including VetDC, GBS and Talu Ventures. Pathway Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter San Francisco, United States
- SectorsHealthcare
- Website ww25.pathwaytx.com/?subid1=20250728-0843-2623-8709-dcb201abc3f0
- Social LinkedIn
- Acquired by VetDC (Aug 2013)
- Legal Name Pathway Therapeutics
Funding Insights of Pathway Therapeutics
Pathway Therapeutics has successfully raised a total of $28.85M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $400 thousand completed in March 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.85M
- Total Rounds 6
- Last Round Series A — $400,000
- First Round $9.6M
(Jun 2008)
- Investors Count 3
All 6 funding rounds of Pathway Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2013 | $400,000 | Series A | – | – | – |
| Nov 2012 | $200,000 | Series A | – | – | – |
| Jun 2011 | $7.5M | Series A | – | GBS, Talu Ventures | – |
| Aug 2010 | $8.75M | Series A | – | GBS | |
| Oct 2009 | $2.4M | Series A | – | GBS, Talu Ventures | – |
| Jun 2008 | $9.6M | Series A | – | GBS, Talu Ventures | – |
4 investors in total: 4 institutional.
Investors in Pathway Therapeutics
Pathway Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include VetDC, GBS and Talu Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | gbsventures.com.au | - | |
Technology investments are managed by Talu Ventures for institutions. | – | taluventures.com | Brisbane, Australia | |
Venture capital investments are targeted through managed funds of funds. | – | nzgcp.co.nz | Auckland, New Zealand | |
Anticancer therapies for animals are developed by VetDC. | 2010 | vet-dc.com | Fort Collins, United States |
Investor details for Pathway Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Pathway Therapeutics
4 dated milestones of Pathway Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Pathway Therapeutics is founded.
- Funding First funding round of $9.6M.
- Funding Latest funding round, Series A, of $400K.
- Exit Acquired by VetDC.
Competitors of Pathway Therapeutics
Pathway Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Pathway Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pathway Therapeutics
Websites that share an audience with Pathway Therapeutics (pathwaytx.com).
Websites whose visitors overlap most with Pathway Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Latest news on Pathway Therapeutics
Complete news archive for Pathway Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Pathway Therapeutics
10 companies that operate in the same segment as Pathway Therapeutics (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pathway Therapeutics
Pathway Therapeutics was founded in 2008.
Pathway Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Pathway Therapeutics is a funded company, having raised a total of $28.85M across 6 funding rounds to date. The company's 1st funding round was a Series A of $9.6M, raised on Jun 2008.
Pathway Therapeutics was founded in 2008 in San Francisco, United States, within the biotechnology sector. Isoform-specific inhibitors targeting the PI3K enzyme are developed for applications in oncology and inflammation. The PI3K pathway is implicated in cancer tumor development, with programs directed toward patient populations most responsive to inhibition. The lead candidate, PWT33597, was acquired by VetDC in 2013.
Pathway Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Pathway Therapeutics has 4 investors. Key investors include VetDC, GBS, Talu Ventures, and New Zealand Growth Capital Partners.
Pathway Therapeutics operates through Pathway Therapeutics.
Yes. Pathway Therapeutics was acquired by VetDC in August 2013.